Point72 Asset Management L.P. Invests $2.32 Million in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Point72 Asset Management L.P. acquired a new stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 2,270,550 shares of the biopharmaceutical company's stock, valued at approximately $2,316,000. Point72 Asset Management L.P. owned about 1.09% of Sangamo Therapeutics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. E Fund Management Co. Ltd. bought a new stake in shares of Sangamo Therapeutics in the fourth quarter valued at $25,000. JPMorgan Chase & Co. increased its holdings in Sangamo Therapeutics by 679.5% in the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 21,793 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in Sangamo Therapeutics by 2,319.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 25,000 shares during the period. SBI Securities Co. Ltd. purchased a new stake in Sangamo Therapeutics during the fourth quarter valued at about $28,000. Finally, Captrust Financial Advisors bought a new position in Sangamo Therapeutics during the fourth quarter worth about $30,000. 56.93% of the stock is owned by institutional investors.

Sangamo Therapeutics Trading Down 4.3%

Shares of SGMO traded down $0.02 during mid-day trading on Monday, reaching $0.47. 2,505,854 shares of the stock traded hands, compared to its average volume of 8,772,639. The company has a market cap of $110.36 million, a price-to-earnings ratio of -0.63 and a beta of 1.46. Sangamo Therapeutics, Inc. has a 1 year low of $0.30 and a 1 year high of $3.18. The firm has a fifty day moving average price of $0.69 and a 200 day moving average price of $1.25.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The business had revenue of $6.44 million for the quarter, compared to the consensus estimate of $7.90 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. On average, sell-side analysts anticipate that Sangamo Therapeutics, Inc. will post -0.46 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on SGMO shares. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research report on Monday, April 7th. Barclays reduced their price objective on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th. Wall Street Zen initiated coverage on Sangamo Therapeutics in a research report on Thursday. They set a "hold" rating on the stock. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $2.00 price target on shares of Sangamo Therapeutics in a report on Tuesday, March 18th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Sangamo Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $4.50.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.